Robert Renninger - 30 Jun 2025 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Reporting relationship: SVP, Finance and Accounting
Issuer ticker: ATHA
Reported as of: 30 Jun 2025
Net transaction value: +$1,462
SEC form: 4
Accepted by SEC: 02 Jul 2025, 16:32:09 UTC
Prior SEC filing: 12 Mar 2025
Next SEC filing: 29 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger

Key filing fact

Robert Renninger filed Form 4 for Athira Pharma, Inc. (ATHA) on 02 Jul 2025.

Key facts

This page summarizes Robert Renninger's Form 4 filing for Athira Pharma, Inc. (ATHA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2025, 16:32.

Change

Previous filing in this sequence was filed on 12 Mar 2025.
Current net transaction value: +$1,462.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002037968 Primary reporting owner

Renninger Robert

Relationship: SVP, Finance and Accounting
Address: C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Signature: /s/ Mark Worthington, Attorney-in-Fact on behalf of Robert Renninger
Signature date: 02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATHA transaction

Common Stock

Award

Transaction value: $2,312
Shares: +10,000
Change %: +11%
Price: $0.2312
Shares after: 99,724
Date: 19 May 2025
Ownership: Direct
Footnotes: F1, F2, F3

ATHA transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +12,359
Change %: +12%
Price: $0.000000
Shares after: 112,083
Date: 30 Jun 2025
Ownership: Direct

ATHA transaction

Common Stock

Sale

Transaction value: $850
Shares: -2,897
Change %: -2.6%
Price: $0.2935
Shares after: 109,186
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATHA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -12,359
Change %: -50%
Price: $0.000000
Shares after: 12,359
Date: 30 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,359
Exercise price
Footnotes: F6, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"),for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2024 through May 19, 2025. This transaction is exempt under Rule 16b-3(c).

Footnote F2

The Purchase Period ended March 19, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2024.

Footnote F3

In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 19, 2025.

Footnote F4

Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.

Footnote F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Footnote F6

RSUs convert into common stock on a one-for-one basis.

Footnote F7

Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.

Footnote F8

On October 1, 2024, the reporting person was granted 37,077 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.